(Q42999261)

English

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

scientific article published on 14 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Masakuni Tateyama

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hiroshi Yatsuhashi

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Naota Taura

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yasuhide Motoyoshi

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Shinya Nagaoka

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kenji Yanagi

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Seigo Abiru

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Koji Yano

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Atsumasa Komori

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kiyoshi Migita

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Minoru Nakamura

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hiroyasu Nagahama

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yutaka Sasaki

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yuzo Miyakawa

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hiromi Ishibashi

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

14 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

92-100

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The natural history of hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Virology. Culture systems for hepatitis C virus in sight at last

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Hepatocellular carcinoma: epidemiology, risk factors, and screening

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Pathogenesis of hepatitis C-associated hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Hepatocellular carcinoma: recent trends in Japan.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

α-fetoprotein: Reevaluation in hepatology

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0293-6

21 January 2018

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of interferon-based therapy for chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of liver biopsy in chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of liver biopsy in management of chronic hepatitis C: a systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711614

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-010-0293-6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42999261&oldid=1976323530"